Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigation of cefiderocol resistance prevalence and resistance mechanisms in carbapenem-resistant Pseudomonas aeruginosa, Germany 2019–21

30 Oct 2024

Abstract excerpt

Abstract Background Cefiderocol, a novel siderophore cephalosporin, is a promising therapeutic option for infections caused by multidrug-resistant Pseudomonas aeruginosa. We evaluated the activity of cefiderocol against carbapenem-resistant P. aeruginosa (Cr-Pa) isolates and investigated the potential mechanisms involved in resistance. Methods 108 CR-Pa isolates collected from patients without prior exposure to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotic Use and Resistance
Share to Antibiotics Pharmacokinetics and Efficacy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39582836
DOI: 10.1093/jacamr/dlae183

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigation of cefiderocol resistance prevalence and resistance mechanisms in carbapenem-resistant Pseudomonas aeruginosa, Germany 2019–21PMID 39582836Read ↗

Emergence of cefiderocol resistance mediated by blaAFM-1 overexpression and FptA mutations in clinical carbapenem-resistant Pseudomonas aeruginosa isolates.Semantic proximity Read ↗

Mechanisms involved in cefiderocol resistance in French <i>Pseudomonas aeruginosa</i> clinical strainsSemantic proximity Read ↗

In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol.Semantic proximity Read ↗

In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain.Semantic proximity Read ↗

Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020-2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program.Semantic proximity Read ↗

Mechanisms of Cefiderocol Resistance in Carbapenemase-Producing <em>Enterobacteriaceae</em>: Insights from Comparative GenomicsSemantic proximity Read ↗

Molecular characteristics of chromosome-mediated colistin resistance in carbapenem-resistant Pseudomonas aeruginosa isolates from a tertiary hospital in China.Semantic proximity Read ↗

Rapid development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway.Semantic proximity Read ↗

In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosaSemantic proximity Read ↗

The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapySemantic proximity Read ↗

In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitorsSemantic proximity Read ↗

Phylogenomic and phenotypic profiling of carbapenem-resistant Pseudomonas aeruginosa clinical isolates reveals lineage-specific resistance mechanisms and adaptive responses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.